|Inception Date||June, 1999|
|Total Value as of 03/19/17||$1,674,791.00|
|Performance, Incept to Date||+167479109999900.00%|
|Performance, Year to Date||+167479000.00%|
|Number of Stocks Held||17|
Ronald Garren, a board certified internist, has been practicing medicine for 30 years. He is a graduate of Harvard Medical School and completed his residency at New York Hospital. His clinical expertise is in the field of oncology. In 1991 he did a three-year postdoctoral fellowship in molecular biology at Stanford in Dr. Paul Berg's lab. During this period he researched the effects of the Nef gene from the HIV virus. An additional year was spent as a visiting scholar in the Biochemistry Dept. at Stanford. After finishing at Stanford, Dr. Garren has continued to practice hospital-based oncology as well as consult for biotech companies in the San Francisco Bay area. He has a founder equity position in Rigel pharmacy, a private biotech company in south San Francisco.
It is this unique combination of experiences that makes his evaluation of the biotech field so compelling. Biotech Insight provides insightful discussion of competing technologies and future advances. Questions such as the importance of a new technology and how will it be accepted by practicing doctors are addressed with skills that few analysts possess. Garren's experience and expertise enables him to present a valuable perspective to individuals interested in investing in biotech.